Whether this is a direct effect to protect the kidney or the indirect benefits of SGLT2 inhibition also reducing AKI-precipitant events, such as HF/volume decompensation, excessive diuretic use or MACE, remains to be established. The gene discussed is SLC5A2; the disease is hydrops fetalis.